Dolor neuropático en cáncer de mama gabapentina versus carbamazepina

SUMMARY OBJECTIVES: The pain neuropatic in breast cancer is for effect of the lesions and the dysfunction in the nervous system it is characterized by alodinia presence, disestesia, parestesias and paroxysms of sharp pain. METHODS: Realized a prospective study, randomized, phase III. to determine the effectiveness, in terms of clinical answer, of the treatment comparative gabapentina with carbamazepina in women with breast cancer stage I, II, III and IV, with sintomatology of pain neuropatic. Which were randomized to receive (arm A) gabapentina doses of 300 mg beginning and every three days you increased 300 mg (25 patients) the (arm B) carbamazepina 200 mg beginning and every three days you increased 200 mg (25 patients) until obtaining complete response or found the biggest established dose. RESULTS: The rates of global response were 63 % in arm A and 25 % in the arm B (P = 0.032) the complete response was 19 % vs 6 % in the arm A and B respectively. The partial response was 44 % (arm A) vs 19 % (arm B). Stable disease 31 % vs 38 % in the arm A and arm B respectively, progression of the disease 6 % in (arm A) and 38 % in (arm B) with similar toxities in both groups. CONCLUSIONS: The treatment outline with gabapentina is more effective and very more tolerated versus carbazepina, in the patient with pain neuropatic and breast cancer disease.